BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37478401)

  • 21. Gene therapy for the Wiskott-Aldrich syndrome.
    Galy A; Thrasher AJ
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):545-50. PubMed ID: 21971332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome.
    Rai R; Romito M; Rivers E; Turchiano G; Blattner G; Vetharoy W; Ladon D; Andrieux G; Zhang F; Zinicola M; Leon-Rico D; Santilli G; Thrasher AJ; Cavazza A
    Nat Commun; 2020 Aug; 11(1):4034. PubMed ID: 32788576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans.
    Castiello MC; Bosticardo M; Pala F; Catucci M; Chamberlain N; van Zelm MC; Driessen GJ; Pac M; Bernatowska E; Scaramuzza S; Aiuti A; Sauer AV; Traggiai E; Meffre E; Villa A; van der Burg M
    J Autoimmun; 2014 May; 50(100):42-50. PubMed ID: 24369837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors.
    Ariga T
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1015-8. PubMed ID: 24168409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.
    Bosticardo M; Marangoni F; Aiuti A; Villa A; Grazia Roncarolo M
    Blood; 2009 Jun; 113(25):6288-95. PubMed ID: 19351959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients.
    Pala F; Morbach H; Castiello MC; Schickel JN; Scaramuzza S; Chamberlain N; Cassani B; Glauzy S; Romberg N; Candotti F; Aiuti A; Bosticardo M; Villa A; Meffre E
    J Clin Invest; 2015 Oct; 125(10):3941-51. PubMed ID: 26368308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wiskott Aldrich Syndrome: A Multi-Institutional Experience From India.
    Suri D; Rikhi R; Jindal AK; Rawat A; Sudhakar M; Vignesh P; Gupta A; Kaur A; Sharma J; Ahluwalia J; Bhatia P; Khadwal A; Raj R; Uppuluri R; Desai M; Taur P; Pandrowala AA; Gowri V; Madkaikar MR; Lashkari HP; Bhattad S; Kumar H; Verma S; Imai K; Nonoyama S; Ohara O; Chan KW; Lee PP; Lau YL; Singh S
    Front Immunol; 2021; 12():627651. PubMed ID: 33936041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
    Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
    Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stable mixed chimerism after hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome.
    Doğu F; Kurtuluş-Ulküer M; Bilge Y; Bozdoğan G; Ulküer U; Malhatun E; Ikincioğullari A; Babacan E
    Pediatr Transplant; 2006 May; 10(3):395-9. PubMed ID: 16677369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How I manage patients with Wiskott Aldrich syndrome.
    Rivers E; Worth A; Thrasher AJ; Burns SO
    Br J Haematol; 2019 May; 185(4):647-655. PubMed ID: 30864154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wiskott-Aldrich Syndrome in four male siblings from a consanguineous family from Lebanon.
    Mansour R; El-Orfali Y; Saber A; Noun D; Youssef N; Youssef Y; Hanna-Wakim R; Dbaibo G; Abboud M; Massaad MJ
    Clin Immunol; 2020 Oct; 219():108573. PubMed ID: 32814211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, Laboratory Features and Clinical Courses of Patients with Wiskott Aldrich Syndrome and X-linked Thrombocytopenia-A single center study.
    Bildik HN; Cagdas D; Ozturk Kura A; Oskay Halacli S; Sanal O; Tezcan I
    Immunol Invest; 2022 Jul; 51(5):1272-1283. PubMed ID: 34098853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.
    Naseem A; Steinberg Z; Cavazza A
    Front Immunol; 2022; 13():966084. PubMed ID: 36059471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
    Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
    Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical features and genotype analysis of 132 patients with Wiskott-Aldrich syndrome].
    Li W; Liu D; Zhang X; Ding Y; Zhao X
    Zhonghua Er Ke Za Zhi; 2015 Dec; 53(12):925-30. PubMed ID: 26887548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genotype of the original Wiskott phenotype.
    Binder V; Albert MH; Kabus M; Bertone M; Meindl A; Belohradsky BH
    N Engl J Med; 2006 Oct; 355(17):1790-3. PubMed ID: 17065640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Confirmed diagnosis of classic Wiskott-Aldrich syndrome in East Africa: a case report.
    Kiputa M; Urio O; Maghembe A; Kombo D; Dhalla S; Ndembo V; Muze K; Kahwa M; Fakih Z; Kija E
    J Med Case Rep; 2022 Jul; 16(1):301. PubMed ID: 35897083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
    Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
    Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.
    Klein C; Nguyen D; Liu CH; Mizoguchi A; Bhan AK; Miki H; Takenawa T; Rosen FS; Alt FW; Mulligan RC; Snapper SB
    Blood; 2003 Mar; 101(6):2159-66. PubMed ID: 12433691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.
    Marangoni F; Bosticardo M; Charrier S; Draghici E; Locci M; Scaramuzza S; Panaroni C; Ponzoni M; Sanvito F; Doglioni C; Liabeuf M; Gjata B; Montus M; Siminovitch K; Aiuti A; Naldini L; Dupré L; Roncarolo MG; Galy A; Villa A
    Mol Ther; 2009 Jun; 17(6):1073-82. PubMed ID: 19259069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.